Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 022083

Expand all

EXELON (RIVASTIGMINE)
4.6MG/24HR Marketing Status: Prescription

Active Ingredient: RIVASTIGMINE
Proprietary Name: EXELON
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 4.6MG/24HR
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022083
Product Number: 001
Approval Date: Jul 6, 2007
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXELON (RIVASTIGMINE)
9.5MG/24HR Marketing Status: Prescription

Active Ingredient: RIVASTIGMINE
Proprietary Name: EXELON
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 9.5MG/24HR
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N022083
Product Number: 002
Approval Date: Jul 6, 2007
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXELON (RIVASTIGMINE)
13.3MG/24HR Marketing Status: Prescription

Active Ingredient: RIVASTIGMINE
Proprietary Name: EXELON
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 13.3MG/24HR
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022083
Product Number: 005
Approval Date: Aug 31, 2012
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English